Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

The Prostate Cancer Drug Market Will More than Double, Increasing from $4.1 Billion in 2011 to $9.1 Billion in 2021



  The Prostate Cancer Drug Market Will More than Double, Increasing from $4.1
  Billion in 2011 to $9.1 Billion in 2021

   Medivation/Astellas Pharma’s Xtandi Will Compete Fiercely With Johnson &
  Johnson/Janssen Biotech/Janssen-Cilag’s Zytiga, According to Findings from
                              Decision Resources

Business Wire

BURLINGTON, Mass. -- November 05, 2012

Decision Resources, one of the world’s leading research and advisory firms for
pharmaceutical and healthcare issues, finds that the prostate cancer drug
market will more than double, increasing from $4.1 billion in 2011 to $9.1
billion in 2021 in the United States, France, Germany, Italy, Spain, the
United Kingdom and Japan. Factors that will drive near-term market growth
include the market expansion of Johnson & Johnson/Janssen
Biotech/Janssen-Cilag’s Zytiga and the uptake of Medivation/Astellas Pharma’s
premium-priced agent, Xtandi.

The Pharmacor Prostate Cancer advisory service finds that, following its U.S.
and European launch in 2011, Zytiga has quickly become the treatment of choice
for docetaxel (Sanofi’s Taxotere, generics)-pretreated metastatic
castrate-resistant prostate cancer (mCRPC). By 2015, less than two years after
its launch, Zytiga is expected to garner major-market peak-year sales of $1.8
billion. Xtandi, an androgen receptor signaling inhibitor, is expected to
compete fiercely with Zytiga for share of the lucrative mCRPC market.
Physician and patient preference as well as cost of these novel hormonal
agents will be critical in shaping prescribing decisions.

“We expect Xtandi to emerge as the patient share leader for chemotherapy-naive
mCRPC and, beginning in 2016, it will become the top-selling agent in the
prostate cancer market through 2021,” said Decision Resources Analyst Rachel
Webster, D. Phil. “We forecast Xtandi will garner sales of $2.2 billion by
2021.”

The findings also reveal that the launch of four novel therapies since 2010
and the anticipated launch of Algeta/Bayer HealthCare’s radium-223
(Alpharadin) in 2013 for symptomatic mCRPC will make this setting an
increasingly crowded and competitive landscape.

The Pharmacor Patient Flow Model for Prostate Cancer, which contains detailed
methodology that includes the modeling of recurrent cases of prostate cancer,
finds that the number of men with prostate cancer who develop metastatic
disease per year—most frequently following metastatic recurrence of
non-metastatic disease—will decline, decreasing by 25 percent over the next 20
years. This trend will primarily be the result of recent declines in the
number of men being diagnosed with prostate cancer and the prolonged length of
time it takes for the disease to metastasize.

The improved overall survival associated with new drug launches will result in
the number of men living with metastatic prostate cancer to exceed half a
million in 2016, from a current level of 436,000. However, the number of men
living with metastatic disease will decline in the longer term as the
decreasing number of men that develop metastatic prostate cancer outweighs
both the effect of population aging and improved survival.

About Pharmacor

Decision Resources’ Pharmacor advisory service offers clients in the
biopharmaceutical industry the most up-to-date information available on
commercially significant disease topics.

About Pharmacor Patient Flow Models

By utilizing our proprietary Pharmacor epidemiological data, Decision
Resources now provides Pharmacor Patient Flow Models covering bladder cancer,
breast cancer, colorectal cancer, head and neck cancer, hepatocellular
carcinoma, gastric cancer, malignant melanoma, non-small-cell lung cancer,
ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma,
sarcoma and thyroid cancer. Using Pharmacor Patient Flow Models, users can
build their own oncology patient flow model and/or validate the logic behind
their own internal models. This interactive tool allows users to track
changing disease and population dynamics over a 20-year annualized forecast,
improve their modeling accuracy with clearly depicted methods and transparent
assumptions and identify untapped market potential within lines of therapy.
Pharmacor Patient Flow Models is available as an add-on product to the
Pharmacor advisory service.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be
       trademarks or registered trademarks of their respective holders.

Contact:

Decision Resources
Christopher Comfort, 781-993-2597
ccomfort@dresources.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement